ISB researchers reveal a darker side of targeted therapy: the same oncogene inhibition that shuts down cancer growth program can also ignite a stress-driven identity switch — revealing an early escape route that may shape the future of cancer treatment
ISB researchers use single-cell sequencing to reveal hidden defenses against bacteriophages — and introduce a powerful new way to study phage-microbe interactions.
New research from ISB’s Gibbons Lab shows that computer models of gut metabolism can predict whether probiotics will successfully establish in an individual’s microbiome and how dietary prebiotics shape health-related molecules in the gut. The findings point toward a future of more personalized, predictable microbiome-based interventions.
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States.